The burden of viral hepatitis C in Europe: A propensity analysis of patient outcomes

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 8, 2012, Pages 869-877

  DaCosta DiBonaventura, Marco ^a   Yuan, Yong ^b   Wagner, Jan Samuel ^a   L'Italien, Gilbert J ^b,d   Lescrauwaet, Benedicte ^e   Langley, Paul ^c  

^a KANTAR HEALTH   (United States)

^b Global Health Economics and Outcomes Research   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Xintera Consulting   (Belgium)

Author keywords

emergency room visits; health status; healthcare provider visits; hepatitis C virus; hospitalizations

Indexed keywords

ABSENTEEISM; ADULT; CONTROLLED STUDY; EMOTIONALITY; FEMALE; FRANCE; GERMANY; HEALTH CARE UTILIZATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; SPAIN; UNITED KINGDOM; VIRUS LOAD;

ADULT; AGED; CASE-CONTROL STUDIES; COST OF ILLNESS; EFFICIENCY; EUROPEAN UNION; FEMALE; HEALTH SERVICES; HEALTH SURVEYS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROPENSITY SCORE; QUALITY OF LIFE;

EID: 84864056217     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283551dee     Document Type: Review

References (33)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
2. Merkinaite S, Lazarus JV, Gore C. Addressing HCV infection in Europe: Reported, estimated and undiagnosed cases. Cent Eur J Public Health 2008; 16:106-110.
3. McHutchison JG, Bacon BR, Owens GS. Making it happen: Managed care considerations in vanquishing hepatitis C. Am J Manag Care 2007; 13:S327-S336.
4. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, et al. Prevalence of hepatitis B and hepatitis C virus infection in France in 2004: Social factors are important predictors after adjusting for known risk factors. J Med Virol 2010; 82:546-555.
5. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: A systematic assessment of incidence, prevalence, morbidity, and morality. BMC Public Health 2009; 9:34.
6. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: Prevalence, burden of disease and screening policies. Stockholm: ecdc; 2010.
7. CEEHRN/EHRN. Hepatitis C prevention, treatment and support among injecting drug users in the new EU member states and neighboring countries: Situation, guidelines and recommendations. Vilnius, Lithuania: EURASIAN Harm Reduction Nework; 2007.
8. Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76:327-332.
9. Touzet S, Kraemer L, Colin C, Pradat P, Lanoir D, Bailly F, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: A critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research). Eur J Gastroenterol Hepatol 2000; 12: 667-678.
10. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 (Suppl 2):30-60.
11. Garcia-Fulgueiras A, Garcia-Pina R, Morant C, Garcia-Ortuzar V, Genova R, Alvarez E. Hepatitis C and hepatitis B-related mortality in Spain. Eur J Gastroenterol Hepatol 2009; 21:895-901.
12. McAvoy NC, Hayes PC. The cirrhosis epidemic in the UK: Evaluating the causes in a European context. Expert Rev Gastroenterol Hepatol 2007; 1:41-45.
13. Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L. The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases. J Med Virol 2005; 75: 522-527.
14. Hatzakis A,Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18:S1-16.
15. Hauser W, Zimmer C, Schiedermaier P, Grandt D. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med 2004; 66:954-958.
16. Cillo U, Amodio P, Ronco C, Soni SS, Zanus G, Minazzato L, et al. Hepatitis C virus adversely affects quality of life. Blood Purif 2011; 32:144-149.
17. Niederau C, Bemba G, Kautz A. Socioeconomic characteristics, quality of life, and state of knowledge of patients with hepatitis C viral infection in Germany: socioeconomic aspects in hepatitis C. Z Gastroenterol 2006; 44:305-317.
18. Cordoba J, Flavia M, Jacas C, Sauleda S, Esteban JI, Vargas V, et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003; 39:231-238.
19. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209-212.
20. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29:264-270.
21. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Kulig CC, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007; 46:420-431.
22. DiBonaventura MD, Wagner JS, Yuan Y, L'Italien G, Langley P, Kim W. Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ 2010; 13:709-718.
23. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010; 52:436-442.
24. Steinke DT,Weston TL, Morris AD, MacDonald TM, Dillon JF. Epidemiology and economic burden of viral hepatitis: An observational population based study. Gut 2002; 50:100-105.
25. United States Census Bureau. International data base: population estimates and projection methodology 2010. Available at http://www.census.gov/ ipc/ www/idb/estandproj.php [Accessed 22 June 2011].
26. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to score version 2 of the SF-12s health survey (with a supplement documenting version 1). Lincoln, RI: QualityMetric Incorporated; 2002.
27. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4:353-365.
28. Prasad M, Wahlqvist P, Shikiar R, Shih YC. A review of self-report instruments measuring health-related work productivity: A patient-reported outcomes perspective. Pharmacoeconomics 2004; 22:225-244.
29. Perrillo R, Rothstein KD, Rubin R, Alam I, Imperial J, Harb G, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon lpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004; 11:157-165.
30. DiBonaventura M, Wagner JS, Yuan Y, L'Italien G, Langley P, Kim W. The impact of hepatitis C on labor force participation, absenteeism, presenteeism, and non-work activities. J Med Econ 2011; 14:253-261.
31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383.
32. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985; 39:33-38.
33. Medicines, Pharmacy & Industry Group, United Kingdom Department of Health. A new value-based approach to the pricing of branded medicines: A consultation. Available at http://www.dh.gov.uk/prod-consum-dh/groups/ dh-digitalassets/@dh/@en/documents/digitalasset/dh-122793.pdf [Accessed 22 June 2011].